WO2005082398A3 - Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de façon differentielle dans les cellules musculaires - Google Patents
Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de façon differentielle dans les cellules musculaires Download PDFInfo
- Publication number
- WO2005082398A3 WO2005082398A3 PCT/US2005/005596 US2005005596W WO2005082398A3 WO 2005082398 A3 WO2005082398 A3 WO 2005082398A3 US 2005005596 W US2005005596 W US 2005005596W WO 2005082398 A3 WO2005082398 A3 WO 2005082398A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- type
- hyperinsulinemia
- diabetes
- diagnosis
- protection against
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05713932A EP1732582A2 (fr) | 2004-02-26 | 2005-02-24 | Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de fa on differentielle dans les cellules musculaires |
CA002557181A CA2557181A1 (fr) | 2004-02-26 | 2005-02-24 | Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de facon differentielle dans les cellules musculaires |
AU2005216922A AU2005216922A1 (en) | 2004-02-26 | 2005-02-24 | Diagnosis of hyperinsulinemia and type II diabetes and protection against same based on genes differentially expressed in muscle cells |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54751204P | 2004-02-26 | 2004-02-26 | |
US60/547,512 | 2004-02-26 | ||
US57934204P | 2004-06-15 | 2004-06-15 | |
US60/579,342 | 2004-06-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005082398A2 WO2005082398A2 (fr) | 2005-09-09 |
WO2005082398A3 true WO2005082398A3 (fr) | 2006-01-26 |
Family
ID=34915602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/005596 WO2005082398A2 (fr) | 2004-02-26 | 2005-02-24 | Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de façon differentielle dans les cellules musculaires |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1732582A2 (fr) |
AU (1) | AU2005216922A1 (fr) |
CA (1) | CA2557181A1 (fr) |
WO (1) | WO2005082398A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
CA2587790A1 (fr) * | 2004-12-07 | 2006-06-15 | Ohio University | Diagnostic de l'hyperinsulinemie et du diabete de type ii et protection contre ceux-ci sur la base de proteines exprimees differemment dans le serum |
GB0512401D0 (en) * | 2005-06-17 | 2005-07-27 | Randox Lab Ltd | Method |
EP1790664A1 (fr) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Anticorps monoclonaux contre claudin-18 pour le traitement du cancer |
CN102333889A (zh) * | 2009-02-27 | 2012-01-25 | 韦尔瓦制药有限公司 | 基于基因表达特征的ⅱ型糖尿病的药物鉴别方案 |
WO2013167153A1 (fr) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Anticorps utiles dans le diagnostic du cancer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000066787A2 (fr) * | 1999-05-05 | 2000-11-09 | Ohio University | Genes et proteines hepatiques pouvant etre regules par l'hormone de croissance, utilisations associees |
WO2004092419A2 (fr) * | 2003-03-31 | 2004-10-28 | Ohio University | Diagnosis de l'hyperinsulinemie et du diabette de type ii et protection correspondante (i) |
-
2005
- 2005-02-24 AU AU2005216922A patent/AU2005216922A1/en not_active Abandoned
- 2005-02-24 EP EP05713932A patent/EP1732582A2/fr not_active Withdrawn
- 2005-02-24 CA CA002557181A patent/CA2557181A1/fr not_active Abandoned
- 2005-02-24 WO PCT/US2005/005596 patent/WO2005082398A2/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000066787A2 (fr) * | 1999-05-05 | 2000-11-09 | Ohio University | Genes et proteines hepatiques pouvant etre regules par l'hormone de croissance, utilisations associees |
WO2004092419A2 (fr) * | 2003-03-31 | 2004-10-28 | Ohio University | Diagnosis de l'hyperinsulinemie et du diabette de type ii et protection correspondante (i) |
Non-Patent Citations (9)
Title |
---|
"CLONTECH.PCR-Select differential screening kit. User Manual", CLONTECH, 10 September 2001 (2001-09-10), pages 1 - 35, XP002307356 * |
BERNAL-MIZRACHI E ET AL: "GENE EXPRESSION PROFILING IN ISLET BIOLOGY AND DIABETES RESEARCH", DIABETES/METABOLISM RESEARCH AND REVIEWS, WILEY, LONDON,, GB, vol. 19, no. 1, 2003, pages 32 - 42, XP008045358, ISSN: 1520-7552 * |
CALVO ROSA MARIA ET AL: "Immunohistochemical and morphometric studies of the fetal pancreas in diabetic pregnant rats. Effects of insulin administration", ANATOMICAL RECORD, vol. 251, no. 2, June 1998 (1998-06-01), pages 173 - 180, XP002332470, ISSN: 0003-276X * |
COROMINOLA H ET AL: "Identification of novel genes differentially expressed in omental fat of obese subjects and obese type 2 diabetic patients", DIABETES, NEW YORK, NY, US, vol. 50, no. 12, December 2001 (2001-12-01), pages 2822 - 2830, XP002293068, ISSN: 0012-1797 * |
GERLACH C ET AL: "PROLIFERATION-ASSOCIATED KI-67 PROTEIN IS A TARGET FOR AUTOANTIBODIES IN THE HUMAN AUTOIMMUNE DISEASE SYSTEMIC LUPUS ERYTHEMATOSUS", LABORATORY INVESTIGATION, UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY, BALTIMORE,, US, vol. 78, no. 1, January 1998 (1998-01-01), pages 129 - 130, XP002073106, ISSN: 0023-6837 * |
LIM H W ET AL: "Identification of differentially expressed mRNA during pancreas regeneration of rat by mRNA differential display", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 299, no. 5, 20 December 2002 (2002-12-20), pages 806 - 812, XP002324520, ISSN: 0006-291X * |
PIETILAEINEN T ET AL: "THE IMPORTANT PROGNOSTIC VALUE OF KI-67 EXPRESSION AS DETERMINED BY IMAGE ANALYSIS IN BREAST CANCER", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, vol. 122, no. 11, 1996, pages 687 - 692, XP008028143, ISSN: 0171-5216 * |
SONE H ET AL: "Pancreatic beta cell senescence contributes to the pathogenesis of type 2 diabetes in high-fat diet-induced diabetic mice.", DIABETOLOGIA. JAN 2005, vol. 48, no. 1, January 2005 (2005-01-01), pages 58 - 67, XP002332471, ISSN: 0012-186X * |
SURWIT R S ET AL: "Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and AJ mice", METABOLISM, CLINICAL AND EXPERIMENTAL, W.B. SAUNDERS CO., PHILADELPHIA, PA, US, vol. 44, no. 5, May 1995 (1995-05-01), pages 645 - 651, XP004540280, ISSN: 0026-0495 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005082398A2 (fr) | 2005-09-09 |
AU2005216922A1 (en) | 2005-09-09 |
CA2557181A1 (fr) | 2005-09-09 |
EP1732582A2 (fr) | 2006-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005082398A3 (fr) | Diagnostic d'hyperinsulinemie et du diabete de type ii et protection contre lesdits etats pathologique grace aux genes exprimes de façon differentielle dans les cellules musculaires | |
WO2007067341A3 (fr) | Compositions et procedes d’augmentation de la sensibilite a l’insuline | |
WO2004089396A3 (fr) | Composes antifongiques et leurs procedes de mise en oeuvre | |
WO2004076639A3 (fr) | Compositions et methodes destinees a diagnostiquer et traiter des maladies auto-immunes | |
EP1745149A4 (fr) | Neuro-proteines utilisees comme biomarqueurs pour deceler une lesion du systeme nerveux et d'autres troubles neurologiques | |
WO2006076691A8 (fr) | Anticorps 2 associes a la translocation de recepteur immunitaire (irta-2) et leurs utilisations | |
WO2006023719A3 (fr) | Mutation genetique indiquant un risque accru de schizophrenie, de trouble schizo-affectif et de trouble bipolaire et applications pour le diagnostic et le traitement de ces maladies | |
WO2004044168A8 (fr) | Rapporteurs fluorescents codes genetiquement presentant des activites de kinase, de methyltransferase et d'acetyltransferase | |
EP2020445A4 (fr) | Détection d'une maladie inflammatoire et composition destinée à la prévention ou au traitement d'une maladie inflammatoire | |
WO2008033427A3 (fr) | Compositions et procédés de détection d'une maladie lysosomale | |
WO2005000335A3 (fr) | Procedes de diagnostic et de traitement lies au vieillissement, en particulier au vieillissement du foie | |
WO2007120156A3 (fr) | Modeles animaux du syndrome du qt long congenital et leurs utilisations | |
WO2004081043A3 (fr) | Variants de baff et leurs methodes d'utilisation | |
WO2006063009A3 (fr) | Diagnostic de l'hyperinsulinemie et du diabete de type ii et protection contre ceux-ci sur la base de proteines exprimees differemment dans le serum | |
WO2006122971A3 (fr) | Traitement de maladies a l'aide d'un systeme d'expression regulee, ameliore | |
WO2006086681A3 (fr) | Methodes d'inhibition de la migration et de la proliferation des cellules musculaires lisses | |
WO2005110460A3 (fr) | Méthodes de traitement et diagnostics relatifs au vieillissement, particulièrement celui des muscles (14.1) | |
WO2004044165A3 (fr) | Proteines associees aux lipides | |
WO2005052182A3 (fr) | Procede d'analyse de contenu de proteine a membrane plasmique de cellules | |
WO2007047335A3 (fr) | Methodes d'utilisation d'antagonistes de baff | |
WO2004094673A8 (fr) | Methodes de surveillance d'activites de medicaments in vivo | |
WO2007025190A3 (fr) | Analyse de localisations pangenomiques | |
WO2007002830A3 (fr) | Diagnostic d'un hyperinsulinisme et d'un diabete de type ii et protection contre ceux-ci a partir de proteines exprimees de façon differentielle dans la peau et identifiees par proteomique | |
WO2004081535A3 (fr) | Etablissement de bases de donnees de profils de structures de proteomes et utilisations desdites bases de donnees | |
WO2005104834A3 (fr) | Gene pnpg5 associe a la douleur |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2557181 Country of ref document: CA Ref document number: 2005216922 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2005216922 Country of ref document: AU Date of ref document: 20050224 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005216922 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005713932 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005713932 Country of ref document: EP |